OBR Daily Commentary

forumImage

CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

(CytoDyn) Jan 13, 2020 - CytoDyn Inc., a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has filed for Breakthrough Therapy designation (BTD) with the U.S. Food and Drug Administration (FDA) for the use of leronlimab as an adjuvant therapy for the treatment of metastatic triple-negative breast cancer (mTNBC). The BTD filing is based on data from the first patient in the Company’s mTNBC Phase 1b/2 trial and an additional single-patient trial under an emergency investigational new drug (IND) protocol evaluating leronlimab for the treatment of HER2+ metastatic, stage 4, breast cancer (MBC).

Read Article arrow

Dean Gesme, MD (Posted: January 13, 2020)

quotesC-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play a significant role in inflammatory disorders and cancer. Antibodies targeting CCR5 are a welcome addition to our antineoplastic armamentarium.quotes

Add Comment 1 Comment
forumImage

SABCS 2019 – AstraZeneca and Daiichi Join the Her2 Resistance

(Vantage) Dec 11, 2019 - New data confirms that trastuzumab deruxtecan has an exciting destiny, but the antibody-drug conjugate’s impressive efficacy in late-stage breast cancer comes at a price.

Read Article arrow

Dean Gesme, MD (Posted: December 12, 2019)

quotesExtremely impressive efficacy in heavily pretreated metastatic HER-2 + breast cancer but the presence of treatment related interstitial lung disease (ILD) is concerning given ILD deaths in over 2% of treated patients and 13.6% all grade ILD. Trials underway in NSCLC and colorectal cancers Will bear close scrutiny for ILD in those populations.quotes

Add Comment 1 Comment
forumImage

Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer

(Bloomberg Businessweek) Oct 10, 2019 - New drugs called “degraders” could take disease-causing proteins out with the trash.

Read Article arrow

Dean Gesme MD FACP FASCO (Posted: October 11, 2019)

quotesProtein degradation has shown considerable efficacy in the form of proteasome inhibitors. Additional approaches to intracellular protein degradation holds considerable promise in the treatment of cancer and many other disease processes.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...